"What" Series

What does interchangeability mean for biological drugs?

22 April 2024
2 min read

Interchangeability in biological drugs refers to a specific biosimilar that is highly similar to the reference (originator) product in terms of quality, safety, and efficacy, and is expected to produce the same clinical effects in any given patient. This means that the biosimilar can be substituted for the reference product by a pharmacist without consulting the prescribing physician, in accordance with state policies, without compromising therapeutic effects or safety.

The evaluation of interchangeability typically requires additional clinical studies to demonstrate that the risk of diminished safety or efficacy from multiple switches or alternating use of the candidate product and the reference product is not greater than the risk from using only the reference product.

In the United States, the FDA has established clear technical regulatory requirements for the interchangeability of biosimilars, while regulatory authorities in other countries have not yet established technical standards for biosimilar interchangeability. Biosimilars that achieve interchangeability status can be used to substitute for the reference product that a patient is currently using and can obtain a one-year market exclusivity period.

It is worth noting that not all biosimilars are deemed interchangeable. Interchangeability certification is an additional step that requires biosimilar manufacturers to conduct additional clinical trials and data submissions to demonstrate that they meet the standards for interchangeability.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 20
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 20
22 April 2024
April 20th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Bristol Myers Squibb Invests in Cancer Immunotherapy Targeting GPR65
DrugDeal Decode
4 min read
Bristol Myers Squibb Invests in Cancer Immunotherapy Targeting GPR65
19 April 2024
Pathios Therapeutics Secures $25M in Series B Funding for Cancer Drug Development.
Read →
Telomir Pharmaceuticals Announces Promising Telomir-1 Anti-Aging Drug Results in D.C. Press Event
Latest Hotspot
3 min read
Telomir Pharmaceuticals Announces Promising Telomir-1 Anti-Aging Drug Results in D.C. Press Event
19 April 2024
Telomir Pharmaceuticals Reveals Promising Early Results for Anti-Aging Medication Telomir-1 at a Press Event in Washington, D.C.
Read →
What is the drug-release principle of sustained-release and controlled-release formulations?
"What" Series
2 min read
What is the drug-release principle of sustained-release and controlled-release formulations?
19 April 2024
Principles of Sustained and Controlled Drug Release for Extended Efficacy and Stable Blood Levels.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.